iStock-962614456_2.jpg

media center

November 24, 2020

Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program

Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA

Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). A first focus of the agreement is the treatment of patients likely to progress into COVID-19-associated acute respiratory distress syndrome (ARDS).

View full press release

October 10, 2020

Ventac Holding USA forms Abbreos, Inc. with an undisclosed shareholder to develop an oral patch to treat certain diseases associated with a cytokine storm.

© 2020 Abbreos

contact us

Abbreos, Inc.
1951 NW 7th Avenue, Ste. 600 Miami, Florida  33136

  • LinkedIn
  • Twitter